InnoVenn expands products and first sales in US

RNS Number : 2395J

Venn Life Sciences Holdings PLC

02 April 2015

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

InnoVenn expands its Labskin product line and confirms first sales to the US

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that InnoVenn, the skin science division of Venn, has extended its product line and seen first sales in the US.

InnoVenn have introduced a new 12 well-plates version of the research grade human skin equivalent, Labskin. Labskin has traditionally been produced in 6 well-plate assays with unique qualities such as its ability to support microflora, improved barrier function and longer test window, positioning it as a world leader in the area of skin science research. The 6 well-plate provides a large area of skin for those requiring easy manipulation, application and sampling. It is ideally suited to large scale samples, repeated sampling and application protocols. In contrast the new 12 well-plates provide the same quality product but in a smaller format for study designs requiring additional technical and biological replicates. It allows Labskin to target a bigger market.

Labskin has established its utility in the cosmetic and dermatological skin research industries with key opinion leaders championing it as a viable alternative to testing products on human or animal skin. The European Union implemented a complete ban on animal testing for cosmetics in March 2013. This ban has led to the market seeking out viable and reliable alternatives for a host of different cosmetic and pharmaceutical products.

InnoVenn has also recently launched its United States service, shipping to a leading cosmetics, personal care and chemical testing group in Michigan who are carrying out tests to measure skin metabolism in different environments.

Commenting on this development Venn CEO, Tony Richardson stated: "This expansion of InnoVenn's product line illustrates that this part of the business is growing independently of the CRO business, which is our strategic plan, allowing InnoVenn to be well positioned to deliver on the full potential of its technology portfolio. Labskin continues to break barriers in terms of its capacity to replicate human skin and colonise microflora and we look forward to bringing Labskin to a global audience."

Enquiries:

Venn Life Sciences Holdings Plc	www.vennlifesciences.com
Tony Richardson, Chief Executive Officer	Tel: [phone]
Orla McGuinness, Marketing Manager	Tel: [phone]
Zeus Capital (Nominated Adviser and Broker)
Ross Andrews/Andrew Jones	Tel: [phone]
Alex Davies	Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About InnoVenn

InnoVenn (55.6% owned by Venn) is a market development accelerator dedicated to rapidly commercialising proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include Labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk

About Venn Life Sciences Limited

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. For more information, visit www.vennlifesciences.com.

 

END

 

 

NRAEFLFBEZFEBBK